|
1
|
Kikuchi K, Rubin BP and Keller C:
Developmental origins of fusion-negative rhabdomyosarcomas. Curr
Top Dev Biol. 96:33–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kikuchi K, Hettmer S, Aslam MI, Michalek
JE, Laub W, Wilky BA, Loeb DM, Rubin BP, Wagers AJ and Keller C:
Cell-cycle dependent expression of a translocation-mediated fusion
oncogene mediates checkpoint adaptation in rhabdomyosarcoma. PLoS
Genet. 10:e10041072014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kikuchi K, Taniguchi E, Chen HI, Svalina
MN, Abraham J, Huang ET, Nishijo K, Davis S, Louden C, Zarzabal LA,
et al: Rb1 loss modifies but does not initiate alveolar
rhabdomyosarcoma. Skelet Muscle. 3:272013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sorensen PH, Lynch JC, Qualman SJ,
Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ and
Barr FG: PAX3-FKHR and PAX7-FKHR gene fusions are prognostic
indicators in alveolar rhabdomyosarcoma: A report from the
children's oncology group. J Clin Oncol. 20:2672–2679. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Epstein JA, Shapiro DN, Cheng J, Lam PY
and Maas RL: Pax3 modulates expression of the c-Met receptor during
limb muscle development. Proc Natl Acad Sci USA. 93:4213–4218.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Christensen JG, Burrows J and Salgia R:
c-Met as a target for human cancer and characterization of
inhibitors for therapeutic intervention. Cancer Lett. 225:1–26.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takayama H, La Rochelle WJ, Anver M,
Bockman DE and Merlino G: Scatter factor/hepatocyte growth factor
as a regulator of skeletal muscle and neural crest development.
Proc Natl Acad Sci USA. 93:5866–5871. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Coltella N, Manara MC, Cerisano V,
Trusolino L, Di Renzo MF, Scotlandi K and Ferracini R: Role of the
MET/HGF receptor in proliferation and invasive behavior of
osteosarcoma. FASEB J. 17:1162–1164. 2003.PubMed/NCBI
|
|
9
|
Koon EC, Ma PC, Salgia R, Welch WR,
Christensen JG, Berkowitz RS and Mok SC: Effect of a
c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on
human ovarian carcinoma cell growth, motility, and invasion. Int J
Gynecol Cancer. 18:976–984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ginsberg JP, Davis RJ, Bennicelli JL,
Nauta LE and Barr FG: Up-regulation of MET but not neural cell
adhesion molecule expression by the PAX3-FKHR fusion protein in
alveolar rhabdomyosarcoma. Cancer Res. 58:3542–3546.
1998.PubMed/NCBI
|
|
11
|
Sharp R, Recio JA, Jhappan C, Otsuka T,
Liu S, Yu Y, Liu W, Anver M, Navid F, Helman LJ, et al: Synergism
between INK4a/ARF inactivation and aberrant HGF/SF signaling in
rhabdomyosarcomagenesis. Nat Med. 8:1276–1280. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferracini R, Olivero M, Di Renzo MF,
Martano M, De Giovanni C, Nanni P, Basso G, Scotlandi K, Lollini PL
and Comoglio PM: Retrogenic expression of the MET proto-oncogene
correlates with the invasive phenotype of human rhabdomyosarcomas.
Oncogene. 12:1697–1705. 1996.PubMed/NCBI
|
|
13
|
Kikuchi K, Tsuchiya K, Otabe O, Gotoh T,
Tamura S, Katsumi Y, Yagyu S, Tsubai-Shimizu S, Miyachi M, Iehara
T, et al: Effects of PAX3-FKHR on malignant phenotypes in alveolar
rhabdomyosarcoma. Biochem Biophys Res Commun. 365:568–574. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lukasiewicz E, Miekus K, Kijowski J,
Drabik G, Wilusz M, Bobis-Wozowicz S and Majka M: Inhibition of
rhabdomyosarcoma's metastatic behavior through downregulation of
MET receptor signaling. Folia Histochem Cytobiol. 47:485–489.
2009.PubMed/NCBI
|
|
15
|
Miekus K, Lukasiewicz E, Jarocha D, Sekula
M, Drabik G and Majka M: The decreased metastatic potential of
rhabdomyosarcoma cells obtained through MET receptor downregulation
and the induction of differentiation. Cell Death Dis. 4:e4592013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Skrzypek K, Kusienicka A, Szewczyk B,
Adamus T, Lukasiewicz E, Miekus K and Majka M: Constitutive
activation of MET signaling impairs myogenic differentiation of
rhabdomyosarcoma and promotes its development and progression.
Oncotarget. 6:31378–31398. 2015.PubMed/NCBI
|
|
17
|
Tsuchiya K, Hosoi H, Misawa-Furihata A,
Houghton PJ and Sugimoto T: Insulin-like growth factor-I has
different effects on myogenin induction and cell cycle progression
in human alveolar and embryonal rhabdomyosarcoma cells. Int J
Oncol. 31:41–47. 2007.PubMed/NCBI
|
|
18
|
Hayashi Y, Sugimoto T, Horii Y, Hosoi H,
Inazawa J, Kemshead JT, Inaba T, Hanada R, Yamamoto K, Gown AM, et
al: Characterization of an embryonal rhabdomyosarcoma cell line
showing amplification and over-expression of the N-myc oncogene.
Int J Cancer. 45:705–711. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Taulli R, Scuoppo C, Bersani F, Accornero
P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M,
Crepaldi T, et al: Validation of met as a therapeutic target in
alveolar and embryonal rhabdomyosarcoma. Cancer Res. 66:4742–4749.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yan D, Dong XE, Chen X, Wang L, Lu C, Wang
J, Qu J and Tu L: MicroRNA-1/206 targets c-Met and inhibits
rhabdomyosarcoma development. J Biol Chem. 284:29596–29604. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marampon F, Bossi G, Ciccarelli C, Di
Rocco A, Sacchi A, Pestell RG and Zani BM: MEK/ERK inhibitor U0126
affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
Mol Cancer Ther. 8:543–551. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma PC, Tretiakova MS, Nallasura V,
Jagadeeswaran R, Husain AN and Salgia R: Downstream signalling and
specific inhibition of c-MET/HGF pathway in small cell lung cancer:
Implications for tumour invasion. Br J Cancer. 97:368–377. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Paumelle R, Tulasne D, Kherrouche Z, Plaza
S, Leroy C, Reveneau S, Vandenbunder B and Fafeur V: Hepatocyte
growth factor/scatter factor activates the ETS1 transcription
factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene.
21:2309–2319. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Okano J, Shiota G, Matsumoto K, Yasui S,
Kurimasa A, Hisatome I, Steinberg P and Murawaki Y: Hepatocyte
growth factor exerts a proliferative effect on oval cells through
the PI3K/AKT signaling pathway. Biochem Biophys Res Commun.
309:298–304. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hosoi H, Dilling MB, Shikata T, Liu LN,
Shu L, Ashmun RA, Germain GS, Abraham RT and Houghton PJ: Rapamycin
causes poorly reversible inhibition of mTOR and induces
p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer
Res. 59:886–894. 1999.PubMed/NCBI
|
|
27
|
Srinivasan R, Zabuawala T, Huang H, Zhang
J, Gulati P, Fernandez S, Karlo JC, Landreth GE, Leone G and
Ostrowski MC: Erk1 and Erk2 regulate endothelial cell proliferation
and migration during mouse embryonic angiogenesis. PLoS One.
4:e82832009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Voisin L, Saba-El-Leil MK, Julien C,
Frémin C and Meloche S: Genetic demonstration of a redundant role
of extracellular signal-regulated kinase 1 (ERK1) and ERK2
mitogen-activated protein kinases in promoting fibroblast
proliferation. Mol Cell Biol. 30:2918–2932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
von Thun A, Birtwistle M, Kalna G,
Grindlay J, Strachan D, Kolch W, von Kriegsheim A and Norman JC:
ERK2 drives tumour cell migration in three-dimensional
microenvironments by suppressing expression of Rab17 and liprin-β2.
J Cell Sci. 125:1465–1477. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Radtke S, Milanovic M, Rossé C, De Rycker
M, Lachmann S, Hibbert A, Kermorgant S and Parker PJ: ERK2 but not
ERK1 mediates HGF-induced motility in non-small cell lung carcinoma
cell lines. J Cell Sci. 126:2381–2391. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sengupta S, Sellers LA, Li RC, Gherardi E,
Zhao G, Watson N, Sasisekharan R and Fan TP: Targeting of
mitogen-activated protein kinases and phosphatidylinositol 3 kinase
inhibits hepatocyte growth factor/scatter factor-induced
angiogenesis. Circulation. 107:2955–2961. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung
L, Chen Y, Huang X, Chan HM, Zhao P, et al: Hepatocyte growth
factor promotes cancer cell migration and angiogenic factors
expression: a prognostic marker of human esophageal squamous cell
carcinomas. Clin Cancer Res. 11:6190–6197. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee J, Seo JW, Jun HJ, Ki CS, Park SH,
Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, et al: Impact of MET
amplification on gastric cancer: Possible roles as a novel
prognostic marker and a potential therapeutic target. Oncol Rep.
25:1517–1524. 2011.PubMed/NCBI
|
|
34
|
Aune G, Lian AM, Tingulstad S, Torp SH,
Forsmo S, Reseland JE, Stunes AK and Syversen U: Increased
circulating hepatocyte growth factor (HGF): A marker of epithelial
ovarian cancer and an indicator of poor prognosis. Gynecol Oncol.
121:402–406. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen Y, Takita J, Mizuguchi M, Tanaka K,
Ida K, Koh K, Igarashi T, Hanada R, Tanaka Y, Park MJ, et al:
Mutation and expression analyses of the MET and CDKN2A genes in
rhabdomyosarcoma with emphasis on MET overexpression. Genes
Chromosomes Cancer. 46:348–358. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rees H, Williamson D, Papanastasiou A,
Jina N, Nabarro S, Shipley J and Anderson J: The MET receptor
tyrosine kinase contributes to invasive tumour growth in
rhabdomyosarcomas. Growth Factors. 24:197–208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jankowski K, Kucia M, Wysoczynski M, Reca
R, Zhao D, Trzyna E, Trent J, Peiper S, Zembala M, Ratajczak J, et
al: Both hepatocyte growth factor (HGF) and stromal-derived
factor-1 regulate the metastatic behavior of human rhabdomyosarcoma
cells, but only HGF enhances their resistance to radiochemotherapy.
Cancer Res. 63:7926–7935. 2003.PubMed/NCBI
|
|
38
|
Breneman JC, Lyden E, Pappo AS, Link MP,
Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer
HM, et al: Prognostic factors and clinical outcomes in children and
adolescents with metastatic rhabdomyosarcoma - a report from the
Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 21:78–84. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nishijo K, Chen QR, Zhang L, McCleish AT,
Rodriguez A, Cho MJ, Prajapati SI, Gelfond JA, Chisholm GB,
Michalek JE, et al: Credentialing a preclinical mouse model of
alveolar rhabdomyosarcoma. Cancer Res. 69:2902–2911. 2009.
View Article : Google Scholar : PubMed/NCBI
|
